载药肝动脉栓塞微球的发展现状  

Development of drug-eluting beads for transarterial chemoembolization

作　　者：金雪锋[1] 陈庆财[1] 宗在伟[1] 许颖[2] 

机构地区：[1]江苏奥赛康药业股份有限公司,南京211112 [2]江苏大学药学院,镇江212013

出　　处：《中国新药杂志》2013年第19期2268-2273,共6页Chinese Journal of New Drugs

摘　　要：载药微球不仅结合了化疗和栓塞的双重作用,而且可在病灶部位缓慢释放药物,长期维持有效药物浓度。与传统化疗栓塞术相比其具有减毒、增效的优势,用于肝细胞癌的治疗已取得了令人鼓舞的成果。本文归纳了化疗栓塞微球载体在几何学、生物学及物理学方面的性质,介绍了前沿最新进展以及明胶微球、DC Bead与HepaSphere等作为化疗药物载体在临床研究与应用的现状,并指出了化疗栓塞微球在载药机理、微球粒径、微球材料等方面的局限性及其将来的发展方向。Drug-eluting beads （DEB） not only combine the dual effects of arterial embolization and targe- ted chemotherapy, but also can release drug slowly and continuously into lesions and maintain therapeutic drug con- centration for a long time. Compared to conventional transcatheter arterial chemoembolization, DEB demonstrate a significant advantage in effect-enhancing and toxicity-reducing action and have showed encouraging results in treat- ment of hepatocelluar carcinoma. In this review, several properties of beads in geometry, biology and physics were briefly discussed; besides, the frontier research advances of DEB also were introduced, together with clinical re- search progresses of gelatin microspheres, DC Bead and HepaSphere as the carriers of chemotherapeutic drugs. At last, this review also summarized some shortcomings of DEB in drug-loading mechanism, bead size, bead mate- rial and so on and proposed directions for future development.

关 键 词：载药洗脱微球 肝细胞癌 动脉化疗栓塞 

分 类 号：R9-1[医药卫生—药学]